TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2038996
Drug: Aspirin (3900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (3900 mg daily for 7 days)
Study: 29420600
Drug: +50% precipitation
Approvals — FDA: no, EMA: no, PMDA: no
Description: +50% precipitation treatment
Study: 29420600
Drug: +33% precipitation
Approvals — FDA: no, EMA: no, PMDA: no
Description: +33% precipitation treatment
Study: 29420600
Drug: -50% precipitation
Approvals — FDA: no, EMA: no, PMDA: no
Description: -50% precipitation treatment
Study: 29420600
Drug: -33% precipitation
Approvals — FDA: no, EMA: no, PMDA: no
Description: -33% precipitation treatment
Study: 25244777
Drug: Ganfule prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ganfule prescription combined with chemotherapy
Study: 22307494
Drug: Oral essential
Normalized name: Eucalyptus essential oil
DrugBank: Eucalyptus oil (DB11114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral essential amino acids (EAAs) 8 g/d for 2 months
Study: 17197463
Drug: Plain bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plain bupivacaine 2.5 mg with fentanyl 15 microg
Study: 17197463
Drug: Hyperbaric bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric bupivacaine 2.5 mg with fentanyl 15 microg
Study: 9895184
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese medicine to invigorate blood and relieve stasis
Study: 28706262
Drug: Alcohol (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (1.5 g/l of body water)
Study: 22128614
Drug: n‐3 polyunsaturated
Approvals — FDA: no, EMA: no, PMDA: no
Description: n‐3 polyunsaturated fatty acids 2 g/day for at least 5 days before surgery and until hospital discharge
Study: 17211567
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of multiple insulin injections and oral repaglinide (1.5 mgr tid)
Study: 11420773
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg estradiol‐17 beta with cyclical dydrogesterone
Study: 8325066
Drug: Inhaled piretanide
Normalized name: piretanide
DrugBank: Piretanide (DB02925)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled piretanide (12 mg)
Study: 8325066
Drug: Inhaled piretanide
Normalized name: piretanide
DrugBank: Piretanide (DB02925)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled piretanide (24 mg)
Study: 8325066
Drug: Inhaled piretanide
Normalized name: piretanide
DrugBank: Piretanide (DB02925)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled piretanide (48 mg)
Study: 31864157
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy (NAC) for ≤ 4 cycles (group 1)
Study: 31864157
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy (NAC) for ≥ 5 cycles (group 2)
Study: 27991894
Drug: Fixed-dose IV
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose IV busulfan (130 mg/m2)
Study: 21940527
Drug: PRECISION TACE
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRECISION TACE with drug-eluting beads (DEB)
Study: 18177513
Drug: Rosiglitazone (RSG)
DrugBank: Rosiglitazone (DB00412)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rosiglitazone (RSG) 8 mg/d
Study: 16456680
Drug: G+MET
Normalized name: Glimepiride + Metformin
Approvals — FDA: no, EMA: no, PMDA: no
Description: G+MET
Study: 15023878
Drug: Etanercept 25
Normalized name: etanercept 25 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept 25 mg twice per week (RENAISSANCE)
Study: 15023878
Drug: Etanercept 25
Normalized name: etanercept 25 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept 25 mg weekly (RECOVER)
Study: 15023878
Drug: Placebo (combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (combined higher doses)
Study: 22748747
Drug: FOR +
Normalized name: Gas for Inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOR + TIO (Formoterol 12 μg twice a day + Tiotropium 18 μg once a day)
Study: 11432696
Drug: Citalopram 10
Normalized name: citalopram 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram 10 mg with Cyproheptadine (4 mg)
Study: 7949021
Drug: Bromocriptine (BC)
DrugBank: Bromocriptine (DB01200)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bromocriptine (BC) treatment
Study: 16463409
Drug: Prior use
Normalized name: Priorix
DrugBank: Rubella virus vaccine (DB10317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prior use of psychiatric medications
Study: 9174890
Drug: Edlan-plasty with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edlan-plasty with implants
Study: 18328090
Drug: Lumiracoxib 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lumiracoxib 100 mg once daily
Study: 24850754
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (control arm)
Study: 27464970
Drug: Cixutumumab (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cixutumumab (20 mg/kg), Pemetrexed (500 mg/m2), Cisplatin (75 mg/m2)
Study: 23456778
Drug: Chemotherapy (gemcitabine‐carboplatin)
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (gemcitabine‐carboplatin)
Study: 19629314
Drug: Usual medical
Normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual medical care and monthly telephone monitoring of administrative and epidemiological nature (Control Group)
Study: 10686210
Drug: Org 31710
Normalized name: ORG-34517
DrugBank: ORG-34517 (DB05423)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Org 31710 (150 mg, every 28 days)
Study: 9583332
Drug: Cognitive-Behavioral Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-Behavioral Treatment (CBT)
Study: 31713710
Drug: Angiotensin receptor/neprilysin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin receptor/neprilysin inhibitor (ARNI)
Study: 25303070
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no aquatic exercise, maintained normal treatments)
Study: 24050577
Drug: S. officinalis
Approvals — FDA: no, EMA: no, PMDA: no
Description: S. officinalis leaf extract (500 mg capsule t.i.d. for 3 months)
Study: 11753809
Drug: Octreoid-Depot 160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreoid-Depot 160 mg i.m. injection once a month plus 20 mg tamoxifen daily
Study: 8388357
Drug: UF heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: UF heparin (2 x 5,000 IU)
Study: 24024838
Drug: 1.25 g
Normalized name: AndroGel 1.25 g Packets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.25 g testosterone gel daily
Study: 24024838
Drug: 2.5 g
Normalized name: Vaporizer 2.5 gallon
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 g testosterone gel daily
Study: 24024838
Drug: 5 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g testosterone gel daily
Study: 24024838
Drug: 10 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g testosterone gel daily
Study: 24024838
Drug: Testosterone gel
Normalized name: Androgel 1.62% Metered Dose Pump Testosterone Gel
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone gel with anastrozole
Study: 14519177
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus nicotine patch
Study: 14519177
Drug: Oral selegiline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral selegiline plus nicotine patch
Study: 10714415
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate 100 mcg b.d.
Study: 10714415
Drug: Zafirlukast 20
Normalized name: zafirlukast 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zafirlukast 20 mg b.d.
Study: 7968325
Drug: Caudal extradural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal extradural morphine group (n = 35)
Study: 3569631
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (CT) (2 to 3 injections/day, self blood glucose monitoring)
Study: 27433887
Drug: Cognitive-behavioral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral treatment (CBT) for childhood anxiety disorders
Study: 12453257
Drug: Not using
Approvals — FDA: no, EMA: no, PMDA: no
Description: Not using oral contraceptives
Study: 8593716
Drug: 200 micrograms/cm2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 micrograms/cm2 of sphinganine in ethanol (50 microliters of a 1.6% solution)
Study: 19775203
Drug: Saracatinib (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saracatinib (250 mg)
Study: 41548
Drug: Dipotassium chlorazepate
Normalized name: Clorazepate Dipotassium
DrugBank: Clorazepic acid (DB00628)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipotassium chlorazepate (15 mg)
Study: 31023750
Drug: Whole-body vibration
Normalized name: Insects (whole body), mite dermatophagoides farinae
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-body vibration (WBV) training, twice a week for 12 weeks
Study: 27839705
Drug: No heat-light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: No heat-light (control) treatment
Study: 8159441
Drug: Ketamine (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (250 mcg/kg i.v. slow push)
Study: 8159441
Drug: Continuous subcutaneous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous subcutaneous infusion of ketamine
Study: 8159441
Drug: Single-dose injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose injections of ketamine
Study: 3124047
Drug: Dantrolene sodium
Normalized name: Dantrolene Sodium
DrugBank: Dantrolene (DB01219)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dantrolene sodium (1.5 mg/kg per day)
Study: 28815341
Drug: Darbepoetin alfa
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Darbepoetin alfa once weekly (QW)
Study: 20135832
Drug: Topical lidocaine‐prilocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical lidocaine‐prilocaine mixture
Study: 20135832
Drug: No topical
Normalized name: Altreno Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: No topical anesthesia (Control)
Study: 18204342
Drug: Atomoxetine 80
Normalized name: atomoxetine 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atomoxetine 80 mg daily for 8 weeks
Study: 15030297
Drug: Novel therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novel therapies targeting post-translational endothelial and mesangial messengers
Study: 8884309
Drug: Canrenoate potassium
Normalized name: canrenoate potassium
DrugBank: Canrenoic acid (DB09015)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canrenoate potassium (200mg in 10ml saline solution)
Study: 8884309
Drug: Placebo (10ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (10ml saline solution)
Study: 6851419
Drug: Chemical stimulation
Normalized name: follicle stimulating hormone / luteinizing hormone Injection [Menopur]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemical stimulation (inhalation of citric acid)
Study: 11394391
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (AB and AC)
Study: 2500068
Drug: UFT-MMC therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: UFT-MMC therapy (400 or 600 mg/day of UFT, plus 6 or 8 mg/body of MMC intravenously weekly for three weeks, then triweekly after six weeks)
Study: 2500068
Drug: UFT-ACR therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: UFT-ACR therapy (400 or 600 mg/day of UFT, plus 20 mg/body of ACR intravenously for 5 serial days every three weeks)
Study: 7933495
Drug: New intraoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: New intraoperative fluid infusion
Study: 639574
Drug: Keratolytic gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Keratolytic gel treatment
Study: 28708072
Drug: CF fortified
Normalized name: californium Cf-249
Approvals — FDA: no, EMA: no, PMDA: no
Description: CF fortified with 2 mg NaFeEDTA plus 3.8 mg FeFum for six days/week (n = 126)
Study: 28708072
Drug: CF fortified
Normalized name: californium Cf-249
Approvals — FDA: no, EMA: no, PMDA: no
Description: CF fortified with 2 mg NaFeEDTA and 3.8 mg FePP for six days/week (n = 127)
Study: 25864858
Drug: Silica-gold nanoparticles
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silica-gold nanoparticles (NP) in a bioengineered on-artery patch
Study: 15801015
Drug: Prasterone 200
Normalized name: prasterone 200 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasterone 200 mg/day
Study: 11445487
Drug: High-dose isoxsuprine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose isoxsuprine hydrochloride (60 mg/day orally)
Study: 7818725
Drug: Acarbose (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acarbose (3 x 50 mg day‐1 for days 1-3; 3 x 100 mg day‐1 for days 4-7)
Study: 21844318
Drug: Vancomycin (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vancomycin (125 mg q.i.d.)
Study: 19552869
Drug: Pharmacologic and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacologic and psychotherapeutic treatments
Study: 15700744
Drug: Silver sulfadiazine
Normalized name: Silver Sulfadiazine
DrugBank: Silver sulfadiazine (DB05245)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silver sulfadiazine cream alone
Study: 3919352
Drug: Nicotine-containing chewing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine-containing chewing gum (2.0 mg)
Study: 29374780
Drug: Compression treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compression treatment (N=82)
Study: 27993804
Drug: Molecularly targeted
Normalized name: Molecular AF
DrugBank: Tolnaftate (DB00525)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Molecularly targeted agents (MTAs) based on tumor molecular profiling
Study: 27993804
Drug: Treatment at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment at physician's choice (TPC)
Study: 18242722
Drug: ALN-RSV01 (150mg,
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALN-RSV01 (150mg, single dose and for five daily doses)
Study: 14515596
Drug: Paint-on gel
Normalized name: Castellani Paint
DrugBank: Phenol (DB03255)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Paint-on gel (18% carbamide peroxide)
Study: 2029499
Drug: Unfiltered boiled
Normalized name: BOIL-EASE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unfiltered boiled coffee (lipid content, 1.0 g/l)
Study: 19409693
Drug: Tadalafil (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tadalafil (all doses)
Study: 8166152
Drug: Ciprofloxacin 500
Normalized name: ciprofloxacin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 500 mg BID
Study: 21708030
Drug: eGFR below
Approvals — FDA: no, EMA: no, PMDA: no
Description: eGFR below 60 ml/min/1.73 m²
Study: 17591648
Drug: PUFA (Arachidonic
Approvals — FDA: no, EMA: no, PMDA: no
Description: PUFA (Arachidonic acid 240 mg/day, Docosahexaenoic acid 240 mg/day)
Study: 1857725
Drug: Calcium supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplementation (3 g as Ca/day)
Study: 1857725
Drug: Normal Calcium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal Calcium intake (536 +/- 2 mg/day)
Study: 28299831
Drug: Ageratina pichinchensis
Normalized name: Ageratina herbacea whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ageratina pichinchensis extract (7% standardized, intravaginally administered for 6 days)
Study: 28299831
Drug: Clotrimazole (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clotrimazole (100 mg, positive control)
Study: 23529834
Drug: Compound Phyllanthus
Normalized name: Phyllanthus niruri top extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compound Phyllanthus Urinaria L. (CPUL) for 3 years
Study: 21739267
Drug: Coadministration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coadministration of fluvoxamine (100 mg/day) with aripiprazole (3 mg)
Study: 2512632
Drug: Ranitidine (dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (dosing at early evening)
Study: 2512632
Drug: Placebo (dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (dosing at nighttime)
Study: 23375965
Drug: 0.4 g
Normalized name: psyllium 0.4 GM Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 g intravenous immunoglobulin per kg every 2 weeks
Study: 23375965
Drug: 0.1 g
Normalized name: BIOTIN 0.1 g in 100 g TOPICAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 g intravenous immunoglobulin per kg every 2 weeks
Study: 21854192
Drug: Ipragliflozin 200
Normalized name: BEXAGLIFLOZIN
DrugBank: Bexagliflozin (DB12236)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipragliflozin 200 mg
Study: 23163880
Drug: Ipragliflozin 300
Normalized name: canagliflozin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipragliflozin 300 mg
Study: 19358784
Drug: Venlafaxine ER
Normalized name: Venlafaxine ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine ER (75-225 mg/d)
Study: 16476042
Drug: Hormone Replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone Replacement Therapy (HRT) - 2 mg of estradiol plus 1 mg norethisterone acetate (n = 20)
Study: 16476042
Drug: Alendronate -
Normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alendronate - 10 mg (n = 18)
Study: 16476042
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of HRT and Alendronate (n = 22)
Study: 8515109
Drug: Albendazole (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albendazole (200 mg; n = 11)
Study: 31702699
Drug: Carbohydrate group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate group (200 mL of apple or grape juice every 3 hours)
Study: 29808711
Drug: Intensive pharmaceutical
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intensive pharmaceutical care
Study: 876324
Drug: Antacid regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antacid regimen
Study: 30538299
Drug: Metformin dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin dosage reduction
Study: 28074788
Drug: 2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg/kg intravenous unfractionated heparin
Study: 28074788
Drug: 3 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg/kg intravenous unfractionated heparin
Study: 24988118
Drug: Daily 7000
Normalized name: ombitasvir
DrugBank: Ombitasvir (DB09296)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Daily 7000 IU vitamin D3 supplementation
Study: 21777268
Drug: Extraction of
Normalized name: tree of heaven pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extraction of 25 hopeless teeth and replacement with conventional or implant-supported fixed partial dentures
Study: 18438234
Drug: CPS (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPS (5 g Cr + 4 g phosphate)
Study: 18438234
Drug: Placebo (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (20 g dextrose)
Study: 10868712
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (750 microg twice daily via Diskus)
Study: 10868712
Drug: Budesonide (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide (800 microg twice daily via Turbuhaler)
Study: 2860157
Drug: 10% PVP‐I
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% PVP‐I ointment mixed with a proteolytic agent
Study: 2860157
Drug: 5% PVP‐I
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% PVP‐I cream with proteolytic agent
Study: 28772248
Drug: Product Evaluation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Product Evaluation Scale (PES) and Drug Effects Questionnaire (DEQ) ratings
Study: 27075314
Drug: NRL001 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: NRL001 10 mg
Study: 17051504
Drug: Ritonavir-boosted protease
Normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ritonavir-boosted protease inhibitor (CPI/r)
Study: 20433721
Drug: Mechanical bowel
Normalized name: ascorbic acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mechanical bowel preparation with polyethylene glycol (Group A)
Study: 20433721
Drug: No mechanical
Approvals — FDA: no, EMA: no, PMDA: no
Description: No mechanical bowel preparation (Group B)
Study: 10170449
Drug: Morphine +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine + midazolam
Study: 7524379
Drug: Reogluman administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reogluman administration
Study: 20130603
Drug: 6-mercaptopurine/methotrexate (MTX)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-mercaptopurine/methotrexate (MTX) maintenance therapy
Study: 16706649
Drug: Antioxidant/NO‐modulating fermented
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant/NO‐modulating fermented papaya preparation (FPP) 9 g/day for 4 weeks
Study: 8404096
Drug: Pyridostigmine (PY)
DrugBank: Pyridostigmine (DB00545)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pyridostigmine (PY) 30 mg orally three times a day
Study: 3780824
Drug: Metoclopramide 1
Normalized name: metoclopramide 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide 1 and 2 mg/kg i.v. X 5
Study: 3595666
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose metoclopramide
Study: 22631865
Drug: Immediate postpartum
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Immediate postpartum etonogestrel implant (IPI) insertion
Study: 17924051
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for hip fractures
Study: 8551821
Drug: Intravenous glyceryl
Normalized name: glyceryl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous glyceryl trinitrate
Study: 28780512
Drug: 30 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/kg dapirolizumab pegol followed by 15 mg/kg every 2 weeks for 10 weeks
Study: 24702239
Drug: 4% articaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4% articaine buccal infiltration (1.8 mL with 1:100,000 epinephrine)